Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Short-term Investments (2016 - 2025)

Regenxbio has reported Short-term Investments over the past 11 years, most recently at $195.6 million for Q4 2025.

  • Quarterly results put Short-term Investments at $195.6 million for Q4 2025, up 10.41% from a year ago — trailing twelve months through Dec 2025 was $195.6 million (up 10.41% YoY), and the annual figure for FY2025 was $195.6 million, up 10.41%.
  • Short-term Investments for Q4 2025 was $195.6 million at Regenxbio, down from $215.4 million in the prior quarter.
  • Over the last five years, Short-term Investments for RGNX hit a ceiling of $281.6 million in Q2 2022 and a floor of $111.5 million in Q3 2021.
  • Median Short-term Investments over the past 5 years was $220.6 million (2024), compared with a mean of $206.8 million.
  • Biggest five-year swings in Short-term Investments: surged 139.31% in 2022 and later tumbled 38.97% in 2025.
  • Regenxbio's Short-term Investments stood at $112.2 million in 2021, then soared by 138.52% to $267.7 million in 2022, then dropped by 10.07% to $240.7 million in 2023, then dropped by 26.41% to $177.2 million in 2024, then grew by 10.41% to $195.6 million in 2025.
  • The last three reported values for Short-term Investments were $195.6 million (Q4 2025), $215.4 million (Q3 2025), and $243.7 million (Q2 2025) per Business Quant data.